Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fortrea Holdings Inc. - Common Stock (NQ:FTRE)

7.055 -0.495 (-6.56%)
Streaming Delayed Price Updated: 3:30 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fortrea Holdings Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
From Pomerantz LLP
Via GlobeNewswire
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest... 
Via StockStory
Bragar Eagel & Squire, P.C. Is Investigating Fortrea and Ibotta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
From Law Offices of Frank R. Cruz
Via Business Wire
FORTREA ALERT: Bragar Eagel & Squire, P.C. is Investigating Fortrea Holdings Inc. on Behalf of Fortrea Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. 
Via StockStory
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks,... 
Via StockStory
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers. 
Via StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
From Law Offices of Frank R. Cruz
Via Business Wire
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,... 
Via Benzinga
Why Fortrea (FTRE) Shares Are Plunging Today
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company delivered weak fourth-quarter 2024 results, with sales, operating profits, and... 
Via StockStory
Fortrea (NASDAQ:FTRE) Misses Q4 Revenue Estimates, Stock Drops
Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 1.8% year on year to $697 million. The company’s full-year revenue... 
Via StockStory
Fortrea Reports Fourth Quarter and Full-Year 2024 Results; Issues Full-Year 2025 Guidance
From Fortrea Holdings Inc
Via GlobeNewswire
Earnings Scheduled For March 3, 2025
Via Benzinga
What To Expect From Fortrea’s (FTRE) Q4 Earnings
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
Fortrea to Add Erin L. Russell to Board of Directors
Fortrea and Starboard enter into Cooperation Agreement 
From Fortrea Holdings Inc
Via GlobeNewswire
1 Healthcare Stock to Hold Forever and 2 to Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research
Fortrea to Sponsor SCRS’ Collaborate Forward Working Group, Encouraging Collaboration for More Efficient Clinical Trials 
From Fortrea Holdings Inc
Via GlobeNewswire
Fortrea Announces Date for Fourth Quarter and Full Year 2024 Financial Results and Conference Call
From Fortrea Holdings Inc
Via GlobeNewswire
Lululemon Athletica To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.